Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative esketamine for postoperative inflammatory response in AIDS patients undergoing anal fistula surgery
ChiCTR2500097012Phase 4Completed
- Sponsor
- Shenzhen Third People's Hospital
- Start
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of esketamine in acquired immunodeficiency syndrome (AIDS), human immunodeficiency virus infection (HIV) and anal fistula (2 arms), sponsored by Shenzhen Third People's Hospital. Primary endpoints: Interleukin-6 (IL-6) and Tumor necrosis factor alpha (TNF-α). Started Feb 2025; status: completed.
02
Drugs
esketamine
03
Conditions
acquired immunodeficiency syndrome (AIDS)human immunodeficiency virus infection (HIV)anal fistula
Beyond the preview
Go deeper on ChiCTR2500097012.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500097012.